NVIC

Interchangeability of COVID-19 Vaccines

Published November 11, 2021

According to a study published in The Lancet on May 12, 2021, adults 50 years and older who received a mixed dose combination of the Pfizer-BioNTech vaccine and the AstraZeneca COVID-19 vaccines experienced more mild and moderate side effects than those administered only one type of vaccine. Systemic reactions, especially fever, were significantly higher after the second vaccine dose in persons who received the AstraZeneca vaccine followed by a dose of the Pfizer-BioNTech vaccine when compared to persons who received two doses of the Pfizer-BioNTech vaccine. There were also more reports of joint and muscle pain, chills, malaise, fatigue, and headache after the second vaccine dose in person who received a mixed dose schedule. 

In late October 2021, the FDA and CDC authorized the mixing of vaccine brand types for all persons receiving booster doses  despite limited safety or efficacy data to support the use of a mixed dose schedule.   

 

Select disease / vaccine